Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

Inclusion criteria:

- Each participant must have completed the short-term trial P05691, and be judged by
the investigator to likely benefit from continued treatment

- Each participant must have demonstrated an acceptable degree of compliance with trial
medication, visits, and other requirements in the short-term trial P05691

Exclusion criteria:

- A participant must not have had any adverse event or other clinically significant
finding(s) in the short-term trial P05691 that would prohibit the subject's
continuation into this long-term extension trial

- A participant must not have any newly diagnosed or discovered psychiatric condition
that would have excluded the subject from participation in the short-term trial
P05691

- A participant must not be at imminent risk of self-harm or harm to others